Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N phase 2 trial in adults with chronic rhinosinusitis with nasal polyps
ChiCTR2300067272Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX005N in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Bilateral nasal endoscopic polyp score. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ChiCTR2300067272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067272.